{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:11:30Z","timestamp":1783987890529,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52188-1","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:42:50Z","timestamp":1778665370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deglycosylation of hepatitis C virus pseudoparticles with 2\u20133,6,8,9 Neuraminidase A elicits protective neutralizing antibodies in mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Jonathan","family":"Cherng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cherng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Nguyen-Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuen-Daw","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-3150","authenticated-orcid":false,"given":"Jaw-Ming","family":"Cherng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"52188_CR1","first-page":"2575","volume-title":"Fields Virology","author":"AB Rickinson","year":"2001","unstructured":"Rickinson, A. B. & Kieff, E. Epstein-Barr virus, 2575\u20132627. In (eds Fields, B. N., Knipe, D. M. & Howley, P. M.) Fields Virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA. (2001).","edition":"4"},{"key":"52188_CR2","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1038\/s41467-022-34961-8","volume":"13","author":"K Sliepen","year":"2022","unstructured":"Sliepen, K. et al. Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. Nat. Commun. 13, 7271 (2022).","journal-title":"Nat. Commun."},{"key":"52188_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tim.2003.12.005","volume":"12","author":"JM Pawlotsky","year":"2004","unstructured":"Pawlotsky, J. M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 12, 96\u2013102 (2004).","journal-title":"Trends Microbiol."},{"key":"52188_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/hep.20819","volume":"42","author":"P Simmonds","year":"2005","unstructured":"Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962\u2013973 (2005).","journal-title":"Hepatology"},{"key":"52188_CR5","doi-asserted-by":"crossref","unstructured":"Luo, G. Molecular virology of hepatitis C virus, p 67\u201385. In Birkhauser JM (ed), Basel, Switzland. (2004).","DOI":"10.1007\/978-3-0348-7903-3_4"},{"key":"52188_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-2007-1007262","volume":"15","author":"J Bukh","year":"1995","unstructured":"Bukh, J., Miller, R. H. & Purcell, R. H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 15, 41\u201363 (1995).","journal-title":"Semin Liver Dis."},{"key":"52188_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/hep.1840190538","volume":"19","author":"P Simmonds","year":"1994","unstructured":"Simmonds, P. et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19, 1321\u20131324 (1994).","journal-title":"Hepatology"},{"key":"52188_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0300-9084(03)00004-X","volume":"85","author":"A Goffard","year":"2003","unstructured":"Goffard, A. & Dubuisson, J. Glycosylation of hepatitis C virus envelope proteins. Biochimie 85, 295\u2013301 (2003).","journal-title":"Biochimie"},{"key":"52188_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/hep.20542","volume":"41","author":"D Lavillette","year":"2005","unstructured":"Lavillette, D. et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41, 265\u2013274 (2005).","journal-title":"Hepatology"},{"key":"52188_CR10","doi-asserted-by":"publisher","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","volume":"79","author":"A Owsianka","year":"2005","unstructured":"Owsianka, A. et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79, 11095\u201311104 (2005).","journal-title":"J. Virol."},{"key":"52188_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20021756","volume":"197","author":"B Bartosch","year":"2003","unstructured":"Bartosch, B., Dubuisson, J. & Cosset, F. L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197, 633\u2013642 (2003).","journal-title":"J. Exp. Med."},{"key":"52188_CR12","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1073\/pnas.0832180100","volume":"100","author":"M Hsu","year":"2003","unstructured":"Hsu, M. et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U S A. 100, 7271\u20137276 (2003).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"52188_CR13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.282.5390.938","volume":"282","author":"P Pileri","year":"1998","unstructured":"Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938\u2013941 (1998).","journal-title":"Science"},{"key":"52188_CR14","doi-asserted-by":"publisher","first-page":"41624","DOI":"10.1074\/jbc.M305289200","volume":"278","author":"B Bartosch","year":"2003","unstructured":"Bartosch, B. et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278, 41624\u201341630 (2003).","journal-title":"J. Biol. Chem."},{"key":"52188_CR15","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","volume":"21","author":"E Scarselli","year":"2002","unstructured":"Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017\u20135025 (2002).","journal-title":"EMBO J."},{"key":"52188_CR16","doi-asserted-by":"publisher","first-page":"14199","DOI":"10.1073\/pnas.2335981100","volume":"100","author":"B Bartosch","year":"2003","unstructured":"Bartosch, B. et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U S A. 100, 14199\u201314204 (2003).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"52188_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s002390010062","volume":"51","author":"M Sala","year":"2000","unstructured":"Sala, M. & Wain-Hobson, S. Are RNA viruses adapting or merely changing? J. Mol. Evol. 51, 12\u201320 (2000).","journal-title":"J. Mol. Evol."},{"key":"52188_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1126\/science.288.5464.339","volume":"288","author":"P Farci","year":"2000","unstructured":"Farci, P. et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339\u2013344 (2000).","journal-title":"Science"},{"key":"52188_CR19","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.3748\/wjg.v11.i19.2874","volume":"11","author":"S Chen","year":"2005","unstructured":"Chen, S. & Wang, Y. M. Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus. World J. Gastroenterol. 11, 2874\u20132884 (2005).","journal-title":"World J. Gastroenterol."},{"key":"52188_CR20","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1073\/pnas.052712599","volume":"99","author":"P Farci","year":"2002","unstructured":"Farci, P. et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. U S A. 99, 3081\u20133086 (2002).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"52188_CR21","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1128\/JCM.41.8.3615-3622.2003","volume":"41","author":"C Gaudy","year":"2003","unstructured":"Gaudy, C. et al. Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome. J. Clin. Microbiol. 41, 3615\u20133622 (2003).","journal-title":"J. Clin. Microbiol."},{"key":"52188_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jhep.2004.01.019","volume":"40","author":"I Abbate","year":"2004","unstructured":"Abbate, I. et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J. Hepatol. 40, 831\u2013836 (2004).","journal-title":"J. Hepatol."},{"key":"52188_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0168-1702(92)90038-B","volume":"22","author":"N Kato","year":"1992","unstructured":"Kato, N. et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res. 22, 107\u2013123 (1992).","journal-title":"Virus Res."},{"key":"52188_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.virol.2006.05.015","volume":"352","author":"M Troesch","year":"2006","unstructured":"Troesch, M. et al. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352, 357\u2013367 (2006).","journal-title":"Virology"},{"key":"52188_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.abb9983","volume":"369","author":"Y Watanabe","year":"2020","unstructured":"Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330\u2013333 (2020).","journal-title":"Science"},{"key":"52188_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41541-023-00635-9","volume":"8","author":"T Patra","year":"2023","unstructured":"Patra, T. et al. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. NPJ Vaccines. 8, 42 (2023).","journal-title":"NPJ Vaccines"},{"key":"52188_CR27","doi-asserted-by":"publisher","first-page":"190290","DOI":"10.1098\/rsob.190290","volume":"10","author":"T Kinoshita","year":"2020","unstructured":"Kinoshita, T. Biosynthesis and biology of mammalian GPI-anchored proteins. Open. Biol. 10, 190290 (2020).","journal-title":"Open. Biol."},{"key":"52188_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1146\/annurev-biophys-060414-034156","volume":"47","author":"M Crispin","year":"2018","unstructured":"Crispin, M., Ward, A. B. & Wilson, I. A. Structure and Immune Recognition of the HIV Glycan Shield. Annu. Rev. Biophys. 47, 499\u2013523 (2018).","journal-title":"Annu. Rev. Biophys."},{"key":"52188_CR29","doi-asserted-by":"publisher","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","volume":"79","author":"A Goffard","year":"2005","unstructured":"Goffard, A. et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79, 8400\u20138409 (2005).","journal-title":"J. Virol."},{"key":"52188_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.virol.2003.10.008","volume":"319","author":"T Slater-Handshy","year":"2004","unstructured":"Slater-Handshy, T., Droll, D. A., Fan, X., Di Bisceglie, A. M. & Chambers, T. J. HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology 319, 36\u201348 (2004).","journal-title":"Virology"},{"key":"52188_CR31","first-page":"71","volume":"9","author":"M Lavie","year":"2007","unstructured":"Lavie, M., Goffard, A. & Dubuisson, J. Assembly of a functional HCV glycoprotein heterodimer. Curr. Issues Mol. Biol. 9, 71\u201386 (2007).","journal-title":"Curr. Issues Mol. Biol."},{"key":"52188_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature01470","volume":"422","author":"X Wei","year":"2003","unstructured":"Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307\u2013312 (2003).","journal-title":"Nature"},{"key":"52188_CR33","doi-asserted-by":"publisher","first-page":"8101","DOI":"10.1128\/JVI.00127-07","volume":"81","author":"F Helle","year":"2007","unstructured":"Helle, F. et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81, 8101\u20138111 (2007).","journal-title":"J. Virol."},{"key":"52188_CR34","doi-asserted-by":"publisher","first-page":"18137","DOI":"10.1073\/pnas.0909696106","volume":"106","author":"CC Wang","year":"2009","unstructured":"Wang, C. C. et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl. Acad. Sci. U S A. 106, 18137\u201318142 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"52188_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0014-5793(03)00635-5","volume":"546","author":"HE Drummer","year":"2003","unstructured":"Drummer, H. E., Maerz, A. & Poumbourios, P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett. 546, 385\u2013390 (2003).","journal-title":"FEBS Lett."},{"key":"52188_CR36","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","volume":"79","author":"D Lavillette","year":"2005","unstructured":"Lavillette, D. et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79, 6023\u20136034 (2005).","journal-title":"J. Virol."},{"key":"52188_CR37","unstructured":"Sambrook, J. & Russell, D. Molecular Cloning 3 edn, Vol. 1 (Cold Spring Harbor Laboratory Press, 2001)."},{"key":"52188_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.imlet.2009.10.005","volume":"128","author":"R Brunner","year":"2010","unstructured":"Brunner, R., Jensen-Jarolim, E. & Pali-Scholl, I. The ABC of clinical and experimental adjuvants\u2013a brief overview. Immunol. Lett. 128, 29\u201335 (2010).","journal-title":"Immunol. Lett."},{"key":"52188_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1440-1681.1994.tb02550.x","volume":"21","author":"GA Johnston","year":"1994","unstructured":"Johnston, G. A. Rand Lecture, ASCEPT. GABA receptors: as complex as ABC? Australaisian Society for Clinical and Experimental Pharmacologists and Toxicologists. Clin. Exp. Pharmacol. Physiol. 21, 521\u2013526 (1994).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"52188_CR40","doi-asserted-by":"publisher","first-page":"18285","DOI":"10.1074\/jbc.M602706200","volume":"281","author":"M Dreux","year":"2006","unstructured":"Dreux, M. et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281, 18285\u201318295 (2006).","journal-title":"J. Biol. Chem."},{"key":"52188_CR41","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1073\/pnas.0504877103","volume":"103","author":"T Pietschmann","year":"2006","unstructured":"Pietschmann, T. et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U S A. 103, 7408\u20137413 (2006).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"52188_CR42","doi-asserted-by":"publisher","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","volume":"78","author":"ZY Keck","year":"2004","unstructured":"Keck, Z. Y. et al. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78, 9224\u20139232 (2004).","journal-title":"J. Virol."},{"key":"52188_CR43","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1128\/JVI.01872-07","volume":"82","author":"JC Meunier","year":"2008","unstructured":"Meunier, J. C. et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82, 966\u2013973 (2008).","journal-title":"J. Virol."},{"key":"52188_CR44","doi-asserted-by":"publisher","first-page":"16269","DOI":"10.1073\/pnas.0705522104","volume":"104","author":"DX Johansson","year":"2007","unstructured":"Johansson, D. X. et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. U S A. 104, 16269\u201316274 (2007).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"52188_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nm1698","volume":"14","author":"M Law","year":"2008","unstructured":"Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14, 25\u201327 (2008).","journal-title":"Nat. Med."},{"key":"52188_CR46","doi-asserted-by":"publisher","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","volume":"8","author":"ZY Keck","year":"2012","unstructured":"Keck, Z. Y. et al. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8, e1002653 (2012).","journal-title":"PLoS Pathog"},{"key":"52188_CR47","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1128\/JVI.06492-11","volume":"86","author":"AW Tarr","year":"2012","unstructured":"Tarr, A. W. et al. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J. Virol. 86, 2739\u20132749 (2012).","journal-title":"J. Virol."},{"key":"52188_CR48","doi-asserted-by":"publisher","first-page":"e66872","DOI":"10.1371\/journal.pone.0066872","volume":"8","author":"R Liu","year":"2013","unstructured":"Liu, R. et al. Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313\u2013327 and 432\u2013443 of hepatitis C virus E1E2 glycoproteins. PLoS One. 8, e66872 (2013).","journal-title":"PLoS One"},{"key":"52188_CR49","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","volume":"88","author":"AW Tarr","year":"2007","unstructured":"Tarr, A. W. et al. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J. Gen. Virol. 88, 2991\u20133001 (2007).","journal-title":"J. Gen. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52188-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:03:25Z","timestamp":1783987405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52188-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52188"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52188-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All care and procedures used in the experiments were in accordance with the ARRIVE guidelines and approved by the Laboratory Animal Service Center, the Office of Research and Development, China Medical University (the animal ethical approval number: CMUIACUC-2021-408).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"21891"}}